Nonfibrillar abeta1-42 inhibits glutamate uptake and phosphorylates p38 in human fibroblasts

Alzheimer Disease and Associated Disorders

Volumn 25, Issue 2, 2011, Pages 164-172

  Zoia, Chiara Paola ^a   Riva, Chiara ^a   Isella, Valeria ^a,b   Proserpio, Paola ^a,b   Terruzzi, Alessandro ^a,b   Arban, Silvia ^a   Salerno, Domenico ^a   Cassina, Valeria ^a   Mantegazza, Francesco ^a   Tremolizzo, Lucio ^a,b   Ferrarese, Carlo ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

ATRA; early Alzheimer disease; energetic impairment; mtROS; oxidative stress; Peripheral model

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMYLOID BETA PROTEIN[1-42]; GLUTAMIC ACID; RETINOIC ACID; SYNAPTOPHYSIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); GLUTAMATE TRANSPORTER; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; AMINO ACID TRANSPORT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; MALE; NECROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SKIN FIBROBLAST; ATOMIC FORCE MICROSCOPY; CELL CULTURE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; FIBROBLAST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID TRANSPORT SYSTEM X-AG; AMYLOID BETA-PEPTIDES; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOWN-REGULATION; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; GLUTAMIC ACID; HUMANS; MALE; MICROSCOPY, ATOMIC FORCE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 79958255411     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181f9860f     Document Type: Article

References (69)

1. Adlard PA, Bush AI. Metals and Alzheimer's disease. JAlzheimer Dis. 2006;10:145-163. (Pubitemid 44763990)
2. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245-4249. (Pubitemid 15053619)
3. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796-807. (Pubitemid 46174498)
4. Opazo C, Huang X, Cherny RA, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem. 2002; 277:40302-40308. (Pubitemid 35215603)
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356. (Pubitemid 34790756)
6. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219-224. (Pubitemid 32204378)
7. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxida-tive stress and neurotoxicity: implications for neurodegenera-tion in Alzheimer's disease brain. Free Radic Res. 2002;36: 1307-1313. (Pubitemid 35469517)
8. Canevari L, Abramov AY, Duchen MR. Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res. 2004;29:637-650. (Pubitemid 38295014)
9. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352-357.
10. Hensley K, Carney JM, Mattson MP, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA. 1994;91:3270-3274.
11. Markesbery WR, Lovell MA. Four-hydroxynonenal, a pro-duct of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 1998;19:33-36. (Pubitemid 28167792)
12. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem. 1990;55:342-345.
13. Mattson MP, Guo Q, Furukawa K, et al. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J Neurochem. 1998;70:1-14. (Pubitemid 28020822)
14. Montine TJ, Neely MD, Quinn JF, et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med. 2002;33:620-626. (Pubitemid 35245834)
15. Smith MA, Rudnicka-Nawrot M, Richey PL, et al. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem. 1995;64:2660-2666.
16. Domingues A, Almeida S, da Cruz e Silva EF, et al. Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits. Neurochem Int. 2007;50:872-880. (Pubitemid 46710199)
17. Ferrer I, Blanco R, Carmona M, et al. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm. 2001; 108:1397-1415. (Pubitemid 34020445)
18. Jin Y, Yan EZ, Fan Y, et al. Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus. Acta Pharmacol Sin. 2005;26: 943-951. (Pubitemid 41153214)
19. Matos M, Augusto E, Oliveira CR, et al. Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience. 2008;156:898-910.
20. Origlia N, Righi M, Capsoni S, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci. 2008;28:3521-3530. (Pubitemid 351469321)
21. Zhu Y, Hou H, Nikolic WV, et al. CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation. PLoS One. 2008;3:e2135.
22. Giovannini MG, Scali C, Prosperi C, et al. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38 MAPK pathway. Neurobiol Dis. 2002;11:257-274. (Pubitemid 36135690)
23. McDonald DR, Bamberger ME, Combs CK, et al. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci. 1998;18:4451-4460. (Pubitemid 28280156)
24. Pyo H, Jou I, Jung S, et al. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport. 1998;9:871-874. (Pubitemid 28179292)
25. Savage MJ, Lin YG, Ciallella JR, et al. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci. 2002;22: 3376-3385. (Pubitemid 37465743)
26. Echeverria V, Ducatenzeiler A, Dowd E, et al. Altered mitogen-activated protein kinase signaling, tau hyperpho-sphorylation and mild spatial learning dysfunction in trans-genic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience. 2004;129: 583-592. (Pubitemid 39487112)
27. Puig B, Gomez-Isla T, Ribe E, et al. Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol. 2004;30:491-502. (Pubitemid 39423036)
28. Hensley K, Floyd RA, Zheng NY, et al. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem. 1999;72: 2053-2058. (Pubitemid 29186010)
29. Johnson GV, Bailey CD. The p38 MAP kinase signaling pathway in Alzheimer's disease. Exp Neurol. 2003;183:263-268. (Pubitemid 37205068)
30. Zhu X, Lee HG, Raina AK, et al. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals. 2002;11:270-281. (Pubitemid 37494394)
31. Gartner U, Holzer M, Arendt T. Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience. 1999;91:1-5. (Pubitemid 29170442)
32. Sun A, Liu M, Nguyen XV, et al. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol. 2003;183:394-405. (Pubitemid 37205081)
33. Webster B, Hansen L, Adame A, et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:142-151.
34. Moreira PI, Harris PL, Zhu X, et al. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis. 2007; 12:195-206. (Pubitemid 47509369)
35. Begni B, Brighina L, Sirtori E, et al. Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease. Free Radic Biol Med. 2004;37:892-901. (Pubitemid 39078558)
36. Pensalfini A, Cecchi C, Zampagni M, et al. Protective effect of new S-acylglutathione derivatives against amyloid-induced oxidative stress. Free Radic Biol Med. 2008;44:1624-1636.
37. Zoia CP, Tagliabue E, Isella V, et al. Fibroblast glutamate transport in aging and in AD: correlations with disease severity. Neurobiol Aging. 2005;26:825-832. (Pubitemid 40249484)
38. Khan TK, Nelson TJ, Verma VA, et al. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts. Neurobiol Dis. 2009;34:332-339.
39. Uberti D, Lanni C, Racchi M, et al. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease. Neurodegener Dis. 2008;5:209-211. (Pubitemid 351347852)
40. Vestling M, Cedazo-Mnguez A, Adem A, et al. Protein kinase C and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer's disease cases. Biochim Biophys Acta. 1999;1453:341-350. (Pubitemid 29146158)
41. Urbanelli L, Emiliani C, Massini C, et al. Cathepsin D expression is decreased in Alzheimer's disease fibroblasts. Neurobiol Aging. 2008;29:12-22. (Pubitemid 350102710)
42. Maden M, Holder N. Retinoic acid and development of the central nervous system. Bioessays. 1992;14:431-438.
43. McCaffery P, Drager UC. Regulation ofretinoic acid signaling in the embryonic nervous system: a master differentiation factor. Cytokine Growth Factor Rev. 2000;11:233-249. (Pubitemid 30337462)
44. Ates-Alagoz Z, Coban T, Buyukbingol E. Synthesis and antioxidant activity of new tetrahydro-naphthalene-indole derivatives as retinoid and melatonin analogs. Arch Pharm (Weinheim). 2006;339:193-200.
45. Chai Z, Yang L, Yu B, et al. p38 mitogen-activated protein kinase-dependent regulation of SRC-3 and involvement in retinoic acid receptor alpha signaling in embryonic cortical neurons. IUBMB Life. 2009;61:670-678.
46. Lee YM, Lee JO, Jung JH, et al. Retinoic acid leads to cytoskeletal rearrangement through AMPK-Rac1 and stimu-lates glucose uptake through AMPK-p38 MAPK in skeletal muscle cells. J Biol Chem. 2008;283:33969-33974.
47. Liu J, Zhou R, He Q, et al. Calmodulin kinase II activation of mitogen-activated protein kinase in PC12 cell following all-trans retinoic acid treatment. Neurotoxicology. 2009;30:599-604.
48. Nicolini G, Miloso M, Zoia C, et al. Retinoic acid differentia-ted SH-SY5Y human neuroblastoma cells: an in vitro model to assess drug neurotoxicity. Anticancer Res. 1998;18:2477-2481. (Pubitemid 28386536)
49. Ferrarese C, Pecora N, Frigo M, et al. Assessment ofreliability and biological significance of glutamate levels in cerebrospinal fluid. Ann Neurol. 1993;33:316-319. (Pubitemid 23081166)
50. Liu Y, Peterson DA, Kimura H, et al. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)reduction. J Neurochem. 1997;69:581-593. (Pubitemid 27327958)
51. Lievre V, Becuwe P, Bianchi A, et al. Intracellular generation of free radicals and modifications of detoxifying enzymes in cultured neurons from the developing rat forebrain in response to transient hypoxia. Neuroscience. 2001;105:287-297. (Pubitemid 32728113)
52. Stine WB Jr, Dahlgren KN, Krafft GA, et al. In vitro characterization of conditions for amyloid-beta peptide oligomer-ization and fibrillogenesis. J Biol Chem. 2003;278:11612-11622. (Pubitemid 36792723)
53. Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener. 2009;4:48-61.
54. Chu B. Laser Light scattering: Basic Principles and Practice. ISBN0121745511. SanDiego. California: Academic Press; 1992.
55. Chromy BA, Nowak RJ, Lambert MP. Self-assembly of Abeta(1-42) into blobular neurotoxins. Biochemistry. 2003;42: 12749-12760.
56. Walsh DM, Lomakin A, Benedek GB, et al. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364-22372. (Pubitemid 27382873)
57. Fernandez-Tome P, Brera B, Arevalo MA, et al. Beta-amyloid25-35 inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism. Neurobiol Dis. 2004;15:580-589. (Pubitemid 38429973)
58. Volterra A, Trotti D, Floridi S, et al. Reactive oxygen species inhibit high-affinity glutamate uptake: molecular mechanism and neuropathological implications. Ann N YAcadSci. 1994; 738:153-162.
59. Lauderback CM, Hackett JM, Huang FF, et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem. 2001;78:413-416. (Pubitemid 32664423)
60. Kadowaki H, Nishitoh H, Urano F, et al. Amyloid induces neuronal cell death through ROS mediated ASK1 activation. Cell Death and Differentiation. 2005;12:19-24. (Pubitemid 40090025)
61. Zhu X, Mei M, Lee HG, et al. P38 activation mediates amyloid-beta cytotoxicity. Neurochem Res. 2005;30:791-796. (Pubitemid 41413936)
62. Li S, Hong S, Shepardson NE, et al. Soluble oligomers of amyloid ß protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62: 788-801.
63. Daniels WM, Hendricks J, Salie R, et al. The role of the MAP-kinase superfamily in beta-amyloid toxicity. Metab Brain Dis. 2001;16:175-185. (Pubitemid 33139218)
64. Gomez-Ramos A, Díaz-Nido J, Smith MA, et al. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res. 2003;71:863-870. (Pubitemid 36293007)
65. Su B, Wang X, Lee HG, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci Lett. 2010; 468:267-271.
66. Tamagno E, Parola M, Bardini P, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem. 2005; 92:628-636. (Pubitemid 40189465)
67. Cecchi C, Pensalfini A, Liguri G, et al. Differentiation increases the resistance of neuronal cells to amyloid toxicity. Neurochem Res. 2008;33:2516-2531.
68. Sahin M, Karauzum SB, Perry G, et al. Retinoic acid isomers protect hippocampal neurons from amyloid-beta induced neurodegeneration. Neurotox Res. 2005;7:243-250.
69. Lee HP, Casadesus G, Zhu X, et al. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother. 2009;9:1615-1621.